Trials / Completed
CompletedNCT00034151
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Achieve Life Sciences · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or primary peritoneal carcinoma.
Detailed description
The goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of S-8184 in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-8184 Paclitaxel Injectable Emulsion |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2002-04-24
- Last updated
- 2009-06-04
Source: ClinicalTrials.gov record NCT00034151. Inclusion in this directory is not an endorsement.